Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346252 · ClinicalTrials.gov registry record · Early Phase 1
The Effect of Botulinum Toxin A on Headache Attributed to TMD
A Early Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03346252: Completed Early Phase 1 study, sponsored by State University of New York at Buffalo.
NCT03346252 is a Early Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03346252, a Early Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.
Primary Outcome
Self-report
Interventions
- DRUG Botulinum Toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2021-03-15 |
| Phase | Early Phase 1 |
What the finished NCT03346252 record still lists
NCT03346252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin type A is the first listed.
NCT03346252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03346252 about?
NCT03346252 is a clinical study titled "The Effect of Botulinum Toxin A on Headache Attributed to TMD". This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.
What is the current status of trial NCT03346252?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-05-08. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT03346252?
The interventions under investigation include: Botulinum Toxin type A (DRUG).
Who is sponsoring clinical trial NCT03346252?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03346252's enrollment target sits among peer trials
20 1157th of 2000 higher than 710 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI